2023 Volume 23 Issue 1 Pages 6-11
In Japan, the number of genetic medical management for BRCA1/2 pathogenic variant carriers is increasing due to the appearance of PARP inhibitors and partial insurance coverage of BRCA1/2 genetic medicine for patients with breast cancer and ovarian cancer. On the other hand, in Europe and the United States, multigene panel testing has become the mainstream of genetic testing. As a result, diagnosis and genetic medicine for various hereditary cancer syndromes have been initiated. Against this background, as the next step in medical treatment for hereditary breast and ovarian cancer syndrome (HBOC), I will discuss the five challenges (purpose, target, gene, risk management, education) to aim for in Japan as well,with evidence from overseas.
